

Figure legends

Figure S1. Days to positive signal in MB/BacTec liquid medium are inversely related to colony forming units / ml (CFU/ml) of *M. tuberculosis* H37Rv.


Figure S2. Days to positive signal in MB/BacTec liquid medium by allocation.

Figure S3. Time to sputum smear conversion by allocation. Error bars, 95% confidence intervals. The number of participants with positive sputum smear remaining in follow-up (number at risk) at 0, 2, 4, 6 and 8 weeks is presented [11].


Table S1. Reasons for ineligibility among individuals assessed for eligibility to participate in the trial (n=214)

| Reason for ineligibility | Number ineligible |
|---|--------------------------|
| Diagnosis other than PTB | 13 |
| Sample other than sputum AFB positive | 23 |
| Age < 18 years | 18 |
| Known sarcoidosis | 1 |
| Known nephrolithiasis | 8 |
| Known HIV infection | 18 |
| Known malignancy | 8 |
| Known renal failure, or serum creatinine > 250 micromol/L | 3 |
| Known hepatic failure | 0 |
| Oral corticosteroid therapy in preceding month | 12 |
| Cytotoxic or other immunosuppressant in preceding month | 1 |
| > 7 days antituberculous therapy in 6 months before enrolment | 32 |
| Taking antituberculous therapy other than HRZE at enrolment | 10 |
| Molecular testing of MTB revealed rpoB mutation | 0 |
| Serum corrected calcium > 2.65 mmol/L | 3 |
| AST / ALT > 120 IU/L or total serum bilirubin > 40 micromol/L | 8 |
| Pregnant / breastfeeding | 11 |
| Combination of >1 of the above | 45 |
| Total | 214 |


Martineau *et al*, Figure S1



Martineau *et al*, Figure S2



Martineau *et al*, Fig S3



Number at risk

| | | | | | |
|-----------|----|----|----|----|----|
| Vitamin D | 62 | 44 | 33 | 27 | 15 |
| Placebo | 64 | 52 | 38 | 28 | 16 |